Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
1995 4
1996 17
1997 6
1998 8
1999 7
2000 7
2001 5
2002 13
2003 11
2004 16
2005 33
2006 27
2007 24
2008 33
2009 26
2010 22
2011 13
2012 16
2013 20
2014 17
2015 16
2016 13
2017 8
2018 13
2019 7
2020 7
2021 9
2022 11
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes in the phase 3 COMMANDS trial. ...The interim efficacy analysis was done for 301 pati …
In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment …
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE. Fishbane S, et al. J Am Soc Nephrol. 2022 Apr;33(4):850-866. doi: 10.1681/ASN.2020111638. J Am Soc Nephrol. 2022. PMID: 35361724 Free PMC article. Clinical Trial.
RESULTS: Among 2133 patients randomized (n=1068 roxadustat, n=1065 epoetin alfa), mean age was 54.0 years, and 89.1% and 10.8% were on hemodialysis and peritoneal dialysis, respectively. ...The proportion of patients experiencing 1 AE and 1 serious AE was 85.0% and …
RESULTS: Among 2133 patients randomized (n=1068 roxadustat, n=1065 epoetin alfa), mean age was 54.0 years, and 89.1% and 10.8% …
Correction of anemia with epoetin alfa in chronic kidney disease.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Singh AK, et al. N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485. N Engl J Med. 2006. PMID: 17108343 Free article. Clinical Trial.
BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. ...METHODS: …
BACKGROUND: Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombi …
Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.
Straus DJ. Straus DJ. Clin Lymphoma. 2003 Aug;4 Suppl 1:S13-7. doi: 10.3816/clm.2003.s.003. Clin Lymphoma. 2003. PMID: 14556671 Review.
Epoetin alfa treatment is optional for patients with cancer-related anemia and hemoglobin levels>10 g/dL and <12 g/dL, depending on clinical circumstances. ...Further evaluation of alternative epoetin alfa dosing schedules and use of epoetin …
Epoetin alfa treatment is optional for patients with cancer-related anemia and hemoglobin levels>10 g/dL and <12 g/dL, d …
Epoetin alfa as an adjuvant to autologous blood donation.
Beris P. Beris P. Semin Hematol. 1996 Apr;33(2 Suppl 2):27-9; discussion 30. Semin Hematol. 1996. PMID: 8723578 Review.
Two clinical studies have been conducted in nonanemic patients to investigate the use of epoetin alfa as an adjuvant to AB predonation to facilitate AB procurement and minimize the development of anemia. ...While there was a trend toward a reduction in allogeneic bl …
Two clinical studies have been conducted in nonanemic patients to investigate the use of epoetin alfa as an adjuvant to AB pre …
Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
Jones M, Schenkel B, Just J. Jones M, et al. Int J Cardiol. 2005 Apr 20;100(2):253-65. doi: 10.1016/j.ijcard.2004.08.051. Int J Cardiol. 2005. PMID: 15823633 Review.
CONCLUSIONS: LVH is common in patients with CRF and CHF. Current findings indicate epoetin alfa therapy results in anemia amelioration, as evidenced by higher Hb and Hct levels, and reduction of key LVH parameters. LVM regression is associated with lower incidence o …
CONCLUSIONS: LVH is common in patients with CRF and CHF. Current findings indicate epoetin alfa therapy results in anemia amel …
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Chen N, et al. N Engl J Med. 2019 Sep 12;381(11):1011-1022. doi: 10.1056/NEJMoa1901713. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31340116 Clinical Trial.
METHODS: In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-stimulating agent therapy with epoetin alfa for at least 6 weeks to receive roxadustat or epoetin alfa three time …
METHODS: In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-s …
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Coyne DW, et al. Clin J Am Soc Nephrol. 2022 Sep;17(9):1325-1336. doi: 10.2215/CJN.00550122. Epub 2022 Aug 2. Clin J Am Soc Nephrol. 2022. PMID: 35918106 Free PMC article. Clinical Trial.
In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in patients on prevalent hemodialysis switching from a prior erythropoiesis-stimulating agent (ESA). ...Mean monthly intravenous iron use was not …
In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in pa …
Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
Kimel M, Leidy NK, Mannix S, Dixon J. Kimel M, et al. Value Health. 2008 Jan-Feb;11(1):57-75. doi: 10.1111/j.1524-4733.2007.00215.x. Value Health. 2008. PMID: 18237361 Free article. Review.
The purpose of this article is to review findings from trials that evaluated the impact of epoetin alfa on HGB and health-related quality of life (HRQL) across various populations with different underlying causes of anemia. ...Statistically significant improvements …
The purpose of this article is to review findings from trials that evaluated the impact of epoetin alfa on HGB and health-rela …
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV; ASCEND-D Study Group. Singh AK, et al. N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5. N Engl J Med. 2021. PMID: 34739194 Clinical Trial.
METHODS: In this randomized, open-label, phase 3 trial, we assigned patients with CKD who were undergoing dialysis and who had a hemoglobin level of 8.0 to 11.5 g per deciliter to receive an oral HIF-PHI (daprodustat) or an injectable ESA (epoetin alfa if they were …
METHODS: In this randomized, open-label, phase 3 trial, we assigned patients with CKD who were undergoing dialysis and who had a hemoglobin …
387 results

Searches related to "epoetin alfa"